Evotec SE(EVO) - 2023 Q4 - Earnings Call Presentation

Revenues with partners in % Total Margin • Just – Evotec Biologics +111% PAGE 14 1 Differences may occur due to rounding Market dynamics and Q4 2023 performance triggered business review PAGE 15 PAGE 16 1. 2023 Performance review 2. Priority reset, Guidance & Outlook 3. Questions & Answers For 2024, we expect to continue operating in a challenging market Summary of current "buyer's market" dynamics PoC: Proof of Concept; IPO: Initial Public Offering; VC: Venture Capital; I&I: Inflammation and Immunology Sou ...